{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumour&page=34",
    "query": {
      "condition": "Advanced Solid Tumour",
      "page": 34
    },
    "page_size": 10
  },
  "pagination": {
    "page": 34,
    "page_size": 10,
    "total_count": 3367,
    "total_pages": 337,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumour&page=35&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumour&page=33&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T06:04:31.417Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01284192",
      "title": "Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignancies",
        "Positive for Anaplastic Lymphoma Kinase",
        "Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS",
        "Solid Tumor",
        "B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "ASP3026",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2010-12",
      "completion_date": "2016-03",
      "has_results": false,
      "last_update_posted_date": "2016-06-28",
      "last_synced_at": "2026-10-16T06:04:31.417Z",
      "location_count": 6,
      "location_summary": "Orange, California • Sacramento, California • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01284192"
    },
    {
      "nct_id": "NCT01313065",
      "title": "Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "VX15/2503",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vaccinex Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2011-01",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2014-08-13",
      "last_synced_at": "2026-10-16T06:04:31.417Z",
      "location_count": 2,
      "location_summary": "Scottsdale, Arizona • San Antonio, Texas",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01313065"
    },
    {
      "nct_id": "NCT00942799",
      "title": "Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Genz-644282 (28-day dosing schedule)",
          "type": "DRUG"
        },
        {
          "name": "Genz-644282 (21-day dosing schedule)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 87,
      "start_date": "2009-07",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2014-03-19",
      "last_synced_at": "2026-10-16T06:04:31.417Z",
      "location_count": 4,
      "location_summary": "Scottsdale, Arizona • Tampa, Florida • Detroit, Michigan + 1 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00942799"
    },
    {
      "nct_id": "NCT00514267",
      "title": "An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer",
        "Tumors"
      ],
      "interventions": [
        {
          "name": "YM 155",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2007-05",
      "completion_date": "2010-03",
      "has_results": false,
      "last_update_posted_date": "2015-08-13",
      "last_synced_at": "2026-10-16T06:04:31.417Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00514267"
    },
    {
      "nct_id": "NCT02030067",
      "title": "Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor",
        "Metastatic Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "RX-3117",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Processa Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 127,
      "start_date": "2013-12",
      "completion_date": "2019-12",
      "has_results": true,
      "last_update_posted_date": "2023-12-06",
      "last_synced_at": "2026-10-16T06:04:31.417Z",
      "location_count": 12,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Duarte, California + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02030067"
    },
    {
      "nct_id": "NCT02110563",
      "title": "Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors",
        "Multiple Myeloma",
        "Non-Hodgkins Lymphoma",
        "Pancreatic Neuroendocrine Tumors",
        "PNET",
        "NHL"
      ],
      "interventions": [
        {
          "name": "DCR-MYC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dicerna Pharmaceuticals, Inc., a Novo Nordisk company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2014-04",
      "completion_date": "2016-11-03",
      "has_results": false,
      "last_update_posted_date": "2024-07-11",
      "last_synced_at": "2026-10-16T06:04:31.417Z",
      "location_count": 6,
      "location_summary": "Stanford, California • Chicago, Illinois • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02110563"
    },
    {
      "nct_id": "NCT00006000",
      "title": "SU5416, Irinotecan, and Cisplatin in Treating Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "irinotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "semaxanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2000-08",
      "completion_date": "2004-03",
      "has_results": false,
      "last_update_posted_date": "2013-01-31",
      "last_synced_at": "2026-10-16T06:04:31.417Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006000"
    },
    {
      "nct_id": "NCT05757492",
      "title": "Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Non-Small Cell Lung Cancer",
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "CHS-006 (anti-TIGIT)",
          "type": "DRUG"
        },
        {
          "name": "toripalimab (anti-PD-1)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Coherus Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2023-04-26",
      "completion_date": "2024-07-31",
      "has_results": false,
      "last_update_posted_date": "2025-05-01",
      "last_synced_at": "2026-10-16T06:04:31.417Z",
      "location_count": 4,
      "location_summary": "Orlando, Florida • Detroit, Michigan • Reno, Nevada + 1 more",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Reno",
          "state": "Nevada"
        },
        {
          "city": "Canton",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05757492"
    },
    {
      "nct_id": "NCT00445458",
      "title": "A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Breast Cancer",
        "Advanced Malignant Solid Tumors",
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "HKI-272",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Puma Biotechnology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2007-09-11",
      "completion_date": "2018-02-07",
      "has_results": true,
      "last_update_posted_date": "2018-07-26",
      "last_synced_at": "2026-10-16T06:04:31.417Z",
      "location_count": 8,
      "location_summary": "La Jolla, California • San Diego, California • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Lansing",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00445458"
    },
    {
      "nct_id": "NCT02419417",
      "title": "Study of BMS-986158 in Subjects With Select Advanced Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Tumors"
      ],
      "interventions": [
        {
          "name": "BMS-986158",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 83,
      "start_date": "2015-06-19",
      "completion_date": "2021-03-17",
      "has_results": true,
      "last_update_posted_date": "2022-06-16",
      "last_synced_at": "2026-10-16T06:04:31.417Z",
      "location_count": 6,
      "location_summary": "Duarte, California • Aurora, Colorado • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02419417"
    }
  ]
}